- Home
- CATO vs ATNM Comparison
CATO vs ATNM Comparison
Compare CATO & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CATO | ATNM |
|---|---|---|
| Founded | 1946 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.5M | 50.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CATO | ATNM |
|---|---|---|
| Price | $3.16 | $1.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 53.5K | ★ 194.3K |
| Earning Date | 11-20-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $660,062,000.00 | $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $42,943.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $2.19 | $1.03 |
| 52 Week High | $4.92 | $2.41 |
Technical Indicators
Market Signals| Indicator | CATO | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 40.42 | 51.57 |
| Support Level | $3.28 | $1.33 |
| Resistance Level | $3.60 | $1.54 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 42.11 | 58.86 |
Price Performance
Historical ComparisonAbout CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.